Mycobacterium paragordonae is an emerging pathogen in human pulmonary disease: clinical features, antimicrobial susceptibility testing and outcomes
- PMID: 35916253
- PMCID: PMC9364734
- DOI: 10.1080/22221751.2022.2103453
Mycobacterium paragordonae is an emerging pathogen in human pulmonary disease: clinical features, antimicrobial susceptibility testing and outcomes
Abstract
Objectives: Mycobacterium paragordonae (MPG) is an emerging and less common type of Non-tuberculous mycobacteria (NTM) and we know little about its characteristics and prognosis, hence we constructed this retrospective cohort study.
Methods: MPG was identified using MALD-TOF MS, multi-target combined gene sequencing and WGS. Clinical information was collected, antimicrobial susceptibility testing was measured using the SLOMYCO panel, and optimal growth temperature testing was measured using Lowenstein-Jensen medium.
Results: Eight MPGs were isolated from 1730 NTMs (0.46%); the mean age of MPG pulmonary disease (MPG-PD) patients was 42.38 ± 9.92 years, 37.5% were male, and the average BMI was 18.4 ± 0.51 kg/m2. All patients had the symptoms of cough and sputum and CT images mainly presented in patchy or streaky shadows, MPG grew at 25°C, 30°C and 37°C, and the optimal growth temperature is 37°C. MPGs were sensitive to clarithromycin, rifabutin, amikacin, linezolid, moxifloxacin, cotrimoxazole and ciprofloxacin, two isolates were resistant to rifampicin. Two patients had follow up information, their imaging remained stable during the follow-up.
Conclusions: MPG-PD is a rare NTM disease and is more likely to develop in middle-aged, female, and low BMI patients. The patients present with no specific features within the symptoms as well as the CT imaging. The optimal growth temperature of MPG is at 37°C, MPG-PD has excellent sensitivity to drugs recommended by CLSI and presents with a stable disease.
Keywords: Mycobacterium paragordonae; antimicrobial susceptibility testing; clinical features; outcomes; pulmonary disease.
Conflict of interest statement
No potential conflict of interest was reported by the author(s).
Figures



Similar articles
-
Mycobacterium paragordonae pulmonary disease with rapidly growing solitary lesions: a case report and literature review.J Infect Dev Ctries. 2024 Oct 31;18(10):1625-1631. doi: 10.3855/jidc.18664. J Infect Dev Ctries. 2024. PMID: 39616474 Review.
-
[Frequently Isolated Slow Growing Nontuberculous Mycobacteria from Pulmonary Samples and Evaluation of Drug Susceptibility Testing Results in a Referral Hospital in Turkey].Mikrobiyol Bul. 2019 Jul;53(3):330-335. doi: 10.5578/mb.68091. Mikrobiyol Bul. 2019. PMID: 31414634 Turkish.
-
Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using slomyco test-system.PLoS One. 2018 Sep 17;13(9):e0203108. doi: 10.1371/journal.pone.0203108. eCollection 2018. PLoS One. 2018. PMID: 30222736 Free PMC article.
-
In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran.Microb Drug Resist. 2016 Mar;22(2):172-8. doi: 10.1089/mdr.2015.0134. Epub 2015 Oct 15. Microb Drug Resist. 2016. PMID: 26468990
-
Antimycobacterial Susceptibility Testing of Nontuberculous Mycobacteria.J Clin Microbiol. 2019 Sep 24;57(10):e00834-19. doi: 10.1128/JCM.00834-19. Print 2019 Oct. J Clin Microbiol. 2019. PMID: 31315954 Free PMC article. Review.
Cited by
-
A Case of Pericarditis and Pericardial Masses Associated With Mycobacterium Paragordonae.Clin Med Insights Cardiol. 2023 Aug 24;17:11795468231189039. doi: 10.1177/11795468231189039. eCollection 2023. Clin Med Insights Cardiol. 2023. PMID: 37637260 Free PMC article.
-
Molecular Characterization and Antibiograms of Nontuberculous Mycobacterium Infections in Kashgar, China.Curr Microbiol. 2025 Jul 11;82(9):376. doi: 10.1007/s00284-025-04357-0. Curr Microbiol. 2025. PMID: 40643789
-
Swollen Necrotic Lymphadenitis Infected with Mycobacterium Paracondontium in an AIDS Patient: a Case Report and Literature Review.Infect Drug Resist. 2024 Aug 9;17:3475-3482. doi: 10.2147/IDR.S473762. eCollection 2024. Infect Drug Resist. 2024. PMID: 39139625 Free PMC article.
References
-
- Daley C, Iaccarino J, Lange C, et al. . Treatment of nontuberculous mycobacterial pulmonary disease: An official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. Clin Infect Dis. 2020;71(4):905–913. - PMC - PubMed
-
- Griffith D. Therapy of nontuberculous mycobacterial disease. Curr Opin Infect Dis. 2007;20(2):198–203. - PubMed
-
- Al-Busaidi I, Wong D, Boggild AK.. Cutaneous Mycobacterium gordonae infection in an elderly diabetic returned traveller. J Travel Med. 2017;24(5). - PubMed
-
- Chang H, Tsai W, Lee T, et al. . Mycobacterium gordonae infection in immunocompromised and immunocompetent hosts: A series of seven cases and literature review. J Formos Med Assoc. 2021;120:524–532. - PubMed
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases